Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody PPR in Third or Later Line Therapy of DLBCL
Status:
RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)